Cantor Fitzgerald Reiterates “$35.00” Price Target for Collegium Pharmaceutical (COLL)

Cantor Fitzgerald set a $35.00 target price on Collegium Pharmaceutical (NASDAQ:COLL) in a research note published on Friday morning. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

Several other research firms have also issued reports on COLL. Zacks Investment Research upgraded Collegium Pharmaceutical from a sell rating to a hold rating in a research note on Wednesday, August 8th. BidaskClub upgraded Collegium Pharmaceutical from a hold rating to a buy rating in a research note on Tuesday, November 27th. Janney Montgomery Scott set a $27.00 price objective on Collegium Pharmaceutical and gave the company a buy rating in a research note on Monday, August 6th. ValuEngine upgraded Collegium Pharmaceutical from a hold rating to a buy rating in a research note on Tuesday, November 13th. Finally, HC Wainwright restated a buy rating on shares of Collegium Pharmaceutical in a research note on Monday, September 17th. One analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company’s stock. Collegium Pharmaceutical has a consensus rating of Buy and an average price target of $31.71.

NASDAQ:COLL opened at $19.19 on Friday. The company has a debt-to-equity ratio of 4.17, a quick ratio of 0.75 and a current ratio of 0.78. Collegium Pharmaceutical has a 12-month low of $13.70 and a 12-month high of $29.90.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Thursday, November 8th. The specialty pharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.14). The business had revenue of $70.20 million during the quarter, compared to the consensus estimate of $74.79 million. Collegium Pharmaceutical had a negative net margin of 30.13% and a negative return on equity of 70.06%. Collegium Pharmaceutical’s quarterly revenue was up 485.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.45) EPS. Research analysts anticipate that Collegium Pharmaceutical will post -1.8 earnings per share for the current year.

In other news, Director Michael Thomas Heffernan sold 25,000 shares of the stock in a transaction that occurred on Monday, October 15th. The stock was sold at an average price of $16.53, for a total transaction of $413,250.00. Following the transaction, the director now owns 361,000 shares in the company, valued at $5,967,330. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 13.87% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Royal Bank of Canada increased its stake in shares of Collegium Pharmaceutical by 9.4% during the first quarter. Royal Bank of Canada now owns 28,238 shares of the specialty pharmaceutical company’s stock worth $721,000 after purchasing an additional 2,437 shares during the period. Rhumbline Advisers increased its stake in shares of Collegium Pharmaceutical by 11.5% during the second quarter. Rhumbline Advisers now owns 28,341 shares of the specialty pharmaceutical company’s stock worth $676,000 after purchasing an additional 2,916 shares during the period. State Board of Administration of Florida Retirement System increased its stake in shares of Collegium Pharmaceutical by 34.7% during the second quarter. State Board of Administration of Florida Retirement System now owns 13,704 shares of the specialty pharmaceutical company’s stock worth $327,000 after purchasing an additional 3,530 shares during the period. Strs Ohio increased its stake in shares of Collegium Pharmaceutical by 13.2% during the second quarter. Strs Ohio now owns 33,500 shares of the specialty pharmaceutical company’s stock worth $798,000 after purchasing an additional 3,900 shares during the period. Finally, Teachers Advisors LLC increased its stake in shares of Collegium Pharmaceutical by 6.2% during the third quarter. Teachers Advisors LLC now owns 77,036 shares of the specialty pharmaceutical company’s stock worth $1,136,000 after purchasing an additional 4,484 shares during the period.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving.

Featured Story: Understanding Average Daily Trade Volume

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit